Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -108.1%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $73M | $269M | — | — | — | — | — | — | — | — |
| Enterprise Value | $55M | $74M | $271M | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.68 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 281.61 | 383.20 | 1143.94 | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.75 | 1.08 | 3.85 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 389.99 | 1153.42 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -717.4% | -717.4% | 100.0% | 100.0% | 83.7% | — | -65.4% | -3228.9% | — | — | — |
| Operating Margin | -40856.3% | -40856.3% | -28899.6% | -15557.8% | -446.8% | — | -152.2% | -5445.0% | — | — | — |
| Net Profit Margin | -39009.5% | -39009.5% | -27243.8% | -14274.5% | -436.5% | — | -155.2% | -5593.1% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -108.1% | -108.1% | -79.9% | -62.3% | -50.3% | -48.0% | -61.8% | -86.3% | -70.5% | -75.9% | -65.1% |
| ROA | -77.6% | -77.6% | -58.9% | -46.6% | -42.9% | -43.8% | -43.3% | -53.1% | -48.6% | -56.8% | -55.0% |
| ROIC | -82.8% | -82.8% | -65.7% | -52.9% | -38.5% | -40.8% | -59.2% | -68.6% | -54.9% | -73.0% | -88.0% |
| ROCE | -96.5% | -96.5% | -73.0% | -59.0% | -48.5% | -47.8% | -56.7% | -70.5% | -54.3% | -62.5% | -62.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.19 | 0.17 | 0.16 | 0.01 | 0.07 | 0.56 | 0.48 | 0.31 | 0.15 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | 0.03 | -0.08 | 0.02 | -0.01 | -0.47 | 0.12 | -0.21 | -0.02 | -0.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.30 | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 | 6.06 | 2.47 | 4.69 | 8.37 | 8.77 |
| Quick Ratio | 5.30 | 5.30 | 5.48 | 6.27 | 5.83 | 18.89 | 6.06 | 2.47 | 4.69 | 8.37 | 8.77 |
| Cash Ratio | 5.19 | 5.19 | 4.82 | 5.98 | 4.77 | 17.95 | 5.40 | 2.41 | 4.57 | 8.19 | 8.46 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.11 | — | 0.27 | 0.01 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 1677.08 | 2696.34 | 2518.81 | 413.81 | — | 71.18 | 86.49 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $93M | $74M | $54M | $28M | $19M | $9M | $3M | $2M | $2M | $2M |
Binary clinical trial failure
Based on reported figures, the company trades at a P/S ratio of 281.61, which appears to reflect extreme market optimism regarding the potential of the efzofitimod platform rather than any tangible, recurring revenue stream currently supported by the firm's underlying financial performance or commercial market presence.
The elevated P/S multiple suggests that investors are pricing the company as a binary option on the success of the EFZO-FIT trial rather than a traditional operating entity. This valuation disconnect warrants caution, as the lack of forward P/E or EBITDA multiples highlights the absence of a fundamental earnings floor to support the current market capitalization.
As reported in financial statements, the company's ROIC has consistently trended in negative territory, reaching -13.4% in 2026Q1, which underscores the structural inability of the current research-heavy business model to generate positive returns on invested capital while the firm remains in the pre-commercial development phase.
The persistent decay in ROIC is a direct consequence of high R&D intensity relative to the lack of commercial revenue. Investors should monitor whether future milestone payments can improve these metrics, though current trends suggest that capital is being consumed at a rate that significantly outpaces the firm's ability to create value.
According to recent SEC filings, the company maintains a current ratio of 5.78 as of 2026Q1, yet this figure masks a precarious cash position of only $10.7 million, which appears insufficient to sustain the firm's high-burn clinical development activities through the next several quarters of operations.
While the current ratio appears superficially healthy, the lack of recurring cash inflows means that the company is highly dependent on external financing or milestone triggers. This liquidity profile suggests that the firm may face an imminent need for dilutive capital to avoid a potential funding gap before the next major clinical data readout.
As indicated by the company's financial disclosures, the P/S ratio is a fundamentally flawed metric for this business model, as it obscures the sporadic, non-recurring nature of milestone-driven revenue and fails to account for the massive, ongoing R&D expenditures required to reach commercialization of the lead asset.
Analysts should instead focus on 'cash runway' and 'R&D efficiency' metrics, as these provide a more accurate assessment of the firm's ability to survive until regulatory milestones are met. Relying on revenue-based valuation multiples in a pre-revenue biotech context may lead to a significant mispricing of the underlying binary risk.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATYR stock.
aTyr Pharma, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
aTyr Pharma, Inc.'s return on equity (ROE) is -108.1%. The historical average is -100.7%.
Based on historical data, aTyr Pharma, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
aTyr Pharma, Inc. has -717.4% gross margin and -40856.3% operating margin.